Aktienanalyse zu Xenon Pharmaceuticals Inc (XENE)XENEXenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenon Pharmaceuticals Inc is currently not a good buy due to significant recent volatility and negative sentiment surrounding its clinical trials. The stock has dropped 25% recently due to a pause in new patient enrollment for clinical studies, which raises concerns about its future growth. While the stock is currently priced at $36.44, analysts have set price targets as high as $73, indicating potential upside, but the recent RSI of 27.531 suggests it is oversold. The main risk is the ongoing uncertainty in clinical trials, particularly with a net loss of $110.7 million reported in Q2 2026, which could impact investor confidence.

3 analysts cover XENE: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.09.